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Abstract
Introduction—Hormonal contraception (HC) use by HIV-infected women has been identified by
the WHO as important strategy for reducing vertical HIV transmission. Little is known about
factors associated with HC discontinuation among HIV-infected women.
Methods—We analyzed data from a prospective study of HC use among 231 HIV-infected oral
contraceptive (OC) or injectable depot medroxyprogesterone acetate (DMPA) users in Uganda and
Zimbabwe. We used Kaplan-Meier survival curves to estimate the median duration of OC and
DMPA use and use of any highly effective contraceptive method. Cox proportional hazards
models were used to investigate factors associated with HC discontinuation.
Results—Median duration was 36 months (95% CI 14, 61) for OC use and 19 months (95% CI
14, 24) for DMPA use. Median duration of any highly effective method was 36 months (95% CI
26, N/A) for OC users and 22 months (95% CI 14, 38) for DMPA users. In multivariable analyses,
living in Zimbabwe (HR 0.39; 95% CI 0.18, 0.83), no partner (HR 7.18; 95% CI 3.05, 16.88) and
cervical infection (HR 1.99; 95% CI 0.90, 4.41) were associated with OC discontinuation. No
partner (HR 2.00; 95% CI 1.12, 3.58), nausea (HR 1.84; 95% CI 1.02, 3.34) and excessive night
sweats (HR 1.80; 95% CI 0.95, 3.40) were associated with DMPA discontinuation.
Discussion—Long-term use of HC methods is acceptable to HIV-infected women. Women
discontinue for a variety of reasons, primarily unrelated to HIV. Alternative methods and ongoing
contraceptive counseling is essential to reduce unplanned pregnancies and vertical HIV
transmission.
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Introduction
Over 16.8 million women are HIV-infected worldwide1. HIV-infected women face complex
reproductive and sexual health choices involving managing their fertility and contraceptive
choices2–4. The use of highly effective contraceptive methods, including hormonal
contraception (HC), by HIV-infected women has been recognized by the WHO as an
important strategy to prevent unintended pregnancies, reduce vertical transmission and
increase a woman’s reproductive control5–7. However, little is known about long-term
patterns of use or factors associated with HC discontinuation among HIV-infected women.
Expanding access to highly active antiretroviral therapy (HAART) likely influences the
fertility intentions and contraceptive needs of HIV-infected women8–12. Changes in the
WHO’s recommended CD4 threshold for HAART initiation has translated into over 8
million people on treatment worldwide7,13. Additionally, improved HAART regimens and
better access to treatment have led to declines in pediatric HIV infections14. Currently,
several countries in sub-Saharan Africa are considering changing national policies to place
all pregnant HIV-infected women on lifelong HAART, regardless of CD4 count15,16. In this
changing context, HIV-infected women need effective options for managing their fertility
and achieving their reproductive goals17.
While HC is highly effective for preventing pregnancy, many healthcare providers
emphasize condom use for HIV-infected women and put less emphasis on use of highly
effective contraception. Healthcare providers may also be reluctant to put HIV-infected
women on HC because of concerns about possible interactions between HC and
antiretroviral drugs, which could theoretically reduce contraceptive or antiretroviral
efficacy18. Concerns have also been raised about whether HC may increase HIV acquisition
in women or transmission to men and/or accelerate disease progression19–21. However,
several recent prospective studies and systematic reviews suggest that HC use is not
associated with time to AIDS, death or HAART initiation, but further investigation is
needed about whether DMPA increases the risk of HIV transmission22–27. In 2012, the
WHO affirmed its recommendation that women living with HIV can continue to use all
existing HC methods without restriction28.
The goal of this study was to examine factors associated with HC use among HIV-infected
women by evaluating use of oral contraceptive pills (OC) and depot medroxygprogesterone
acetate (DMPA) over an eight year period in a prospective cohort study of HIV-infected
women in Uganda and Zimbabwe. The specific objectives of this analysis are (1) to describe
the median duration of HC use among HIV-infected OC and DMPA users through a) first
method-specific discontinuation and b) discontinuation of a highly effective method and (2)
to examine factors associated with discontinuation of HC among HIV-infected OC and
DMPA users.
Methods
We analyzed data from a prospective study of HC use among women who became HIV-
infected while participating in the Hormonal Contraception and Risk of HIV Acquisition
(HC-HIV) Study and a subsequent study of contraceptive use among HIV-infected women
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(Hormonal Contraception and HIV-1 Genital Shedding and Disease Progression (GS)
Study) conducted from 2001 to 2009. Study procedures have been described previously29.
Briefly, we recruited 86 Ugandan and 145 Zimbabwean (n=231) HIV-infected women ages
18 to 45 years who used either DMPA (150 mg administered quarterly), OCs (low-dose pills
containing 30 mcg ethinyl estradiol and 150 mcg of levonorgestrel), or no hormonal method.
Women were ineligible if they had an abortion or miscarriage in the 10 days prior to
screening or if they had undergone hysterectomy. The institutional review boards of
collaborating institutions in the United States, Uganda and Zimbabwe approved the study.
All women provided written informed consent prior to study participation.
We conducted follow-up visits at 4, 8, and 12 weeks after enrollment and at 12-week
intervals thereafter. At each study visit, women were interviewed about their contraceptive
use, sexual behavior and reproductive health. We provided contraceptive, HIV risk
reduction, and condom use counseling and free contraceptives and condoms. Each study
visit also included physical examinations, pregnancy and reproductive tract infections
(RTIs) testing as previously described30. We treated participants on-site for vaginal
infections and recalled women diagnosed with asymptomatic chlamydia, gonorrhea, or
syphilis for treatment. Beginning in 2003, we offered HAART and trimethoprim–
sulfamethoxazole to women who developed severe symptoms of HIV infection (WHO
clinical stage 4 or severe stage 3) or who within a six-month period had two CD4 counts ≤
200 cells/mm3, in accordance with national ARV guidelines at the time.
For the analyses of contraceptive discontinuation and risk factors, we analyzed HIV-infected
participants with at least one follow-up visit with valid contraceptive use data who (1) used
either OCs or DMPA at the start of the GS study or (2) were not using HC at study
enrollment but began using it during follow-up. For women using OCs or DMPA at
enrollment, the contraceptive start date was the date of their first study visit. For women
who began using OCs or DMPA during follow-up, the contraceptive start date was the first
visit at which they reported OC or DMPA use. At each study visit, women were asked about
contraceptive use since their last visit and reported start and stop dates for any method used.
Time to discontinuation was calculated as the number of months from contraceptive start
date to date of method discontinuation. For OC users, discontinuation was defined as any
gap in the start and stop dates for OC use. For DMPA users, discontinuation was defined as
not returning for an injection within 121 days of a woman’s last injection.
Our primary endpoint was the number of months from the contraceptive start date to either
(1) method-specific contraceptive discontinuation or (2) the last study contact, whichever
occurred earlier. A secondary endpoint was defined as the number of months from the
contraceptive start date to (1) stopping use of a highly effective method (defined as OC,
DMPA, IUD, implants or sterilization) or (2) the last study contact, whichever occurred
earlier. For women who became pregnant during follow-up, if the estimated pregnancy date
occurred prior to the date of method of discontinuation they were not counted as
discontinuing their method and were right censored at the estimated pregnancy date. Women
contributed person-time on a method prior to becoming pregnant, but were censored at their
estimated pregnancy date because they would no longer eligible to discontinue
contraception. Because HAART was not available throughout the entire study period,
women who initiated HAART or who underwent hysterectomy were right-censored at the
visit of the event.
We calculated the median number of months from contraceptive start date to method-
specific discontinuation for all women who used HC during the study period. We compared
the probability of discontinuation in OC and DMPA users over time using Kaplan–Meier
survival analysis and log-rank tests. We conducted two sensitivity analyses. For the first, the
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contraceptive start date was calculated retrospectively going back before enrollment based
on contraceptive calendar information obtained at the first study visit. The retrospective start
date was not used as the primary contraceptive start date because covariate information
between seroconversion and study entry was not available for all women. Because we were
interested in understanding HC use after HIV-infection, person-time for women who
continuously used OCs or DMPA before HIV infection were truncated at their estimated
date of HIV infection. In the second, the analysis population was restricted to women on HC
at their first study visit.
We evaluated factors related to OC or DMPA method-specific discontinuation (primary
endpoint) using Cox proportional hazards models. Factors significant in bivariate analyses
(at alpha ≤ 0.10) were included in full multivariable models and variables were eliminated
using backwards selection with an alpha 0.10 cut-off. We decided to include a priori the
following variables in all multivariable models: country, age and CD4 count. To estimate the
effect of time-varying variables (e.g. sexual behaviors, condom use) on method
discontinuation, a participant's time was divided into segments corresponding to the periods
between study visits30. All analyses were conducted using SAS statistical software, version
9.3 (SAS Institute, Cary, NC).
Results
Of 231 enrolled women, 62 (27%) used OCs and 128 (55%) used DMPA at their first study
visit. An additional 18 (8%) began OCs and 23 (10%) began DMPA during follow up.
DMPA use was more popular than OCs, with 151 (65%) women either using DMPA at
baseline or initiating use during follow up (Table 1). Women contributed a total of 1886
visit segments and were followed for a mean of 25 months and a median of 16 months. Over
the follow-up period, 151 women discontinued their original method; 41 (18%) OC users
and 110 (48%) DMPA users. Twenty (9%) women were censored due to pregnancy and 18
(8%) due to HAART initiation. The cumulative pregnancy rate was higher in Uganda (14.4
per100 person years) than Zimbabwe (7.7 per100 person years). The combined cumulative
pregnancy rate was 10.1 per 100 person years31.
Women in the study were approximately equally distributed among the age groups 19–24,
25–29 and 30+. The majority of women had at least two children (78%) and reported 0–14
sexual acts in a typical month (72%). Among women with partners, self-reported condom
use was high but inconsistent; only 60 (26%) women reported always using a condom. Only
16 (7%) reported no condom use due to no partner (Table 1).
HIV-related side effects such as excessive night sweats and loss of appetite or weight were
uncommon. Nausea was slightly higher among DMPA than OC users (7% vs 3%). Slightly
more OC than DMPA users had a current cervical infection (CT or GC) at baseline (13% vs
9%). CD4 counts in the study population were relatively high at baseline; 125 (54%) had
CD4 counts ≥500 cells/mm3 (Table 1).
Over the eight year study period, OC users continued on their method about twice as long as
DMPA users. The median time to discontinuation for OC users was 35 months (95% CI 14,
61) and 19 months (95% CI 14, 24) for DMPA users (Figure 1). However, among women in
Uganda the median times to discontinuation for each method were nearly identical; 21
months (95% CI 6, 36) for OC users and 21 months (95% CI 14, 31) for DMPA users.
Conversely, in Zimbabwe median DMPA use was 17 months (95% CI 12, 24) while OC
discontinuation never reached the median (50th) percentile (Figure 2). Similar trends were
seen in sensitivity analyses when the duration of contraceptive use included time before
enrollment (36 months for OCs; 21 months for DMPA) and likewise, when the analysis
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population was restricted to women on HC at study enrollment (36 months for OCs; 16
months for DMPA). Within the first year of use, discontinuation did not vary by method
(36% of OC users and 37% of DMPA users).
At the time of discontinuation, women were asked the main reason for not continuing use of
their current method. Of five possible answers, other non-medical reasons (such as no longer
having a sexual partner) was the most common (32%), followed by bleeding problems (9%),
other side-effects (8%), desires/desired pregnancy (3%) and unintended pregnancy (2%).
Bleeding problems were more commonly cited as a reason for discontinuation among
DMPA users (11% vs 2% among OC users), whereas ‘other’ side-effects was more
commonly cited among OC users (12% vs 6% for DMPA users). Results were similar for
reasons for discontinuation of any highly effective method; with a slightly higher proportion
reporting desires/desired pregnancy (3%) and unintended pregnancy (3%).
The median time to discontinuation of any highly effective method was also 36 months
(95% CI 26, NA) for OC users and 22 months (95% CI 14, 38) for DMPA users. Compared
to the median time to method-specific discontinuation, median use of any highly effective
method was shorter for DMPA users in Uganda (16 months; 95% CI 11, 38) and longer for
DMPA users in Zimbabwe (32 months; 95% CI 12, 49). We found a significant country by
method interaction for the hazard of discontinuation (p-value 0.01), and therefore
constructed separate multivariable models for OC and DMPA users.
Among women who discontinued their original method but stayed on a highly effective
method, all 12 originally on OCs switched to DMPA at their first visit after discontinuing
OCs. Among 26 DMPA users who switched to another highly effective method, 25 (96%)
switched to OCs and one woman had tubal ligation. At the visit a woman discontinued her
original method, 28 (68%) of OC users and 87 (79%) of DMPA users reported having a
primary partner.
In bivariable analyses among OC users, younger age (19–24), never using a condom, no
sexual partner, participant behavioral risk (defined as multiple partners, new partner,
commercial sex work or had sex with another man in the last 3 months) and having a current
cervical infection were associated with an increased hazard of OC discontinuation. Increased
coital frequency (15–29 acts) and living in Zimbabwe were protective against OC
discontinuation. In multivariable analyses, living in Zimbabwe remained significantly
protective against OC discontinuation (HR 0.39; 95% CI 0.18, 0.83), while not having a
partner (HR 7.18; 95% CI 3.05, 16.88) remained associated with an increased hazard of
discontinuation and current cervical infection (HR 1.99; 95% CI 0.90, 4.41) was marginally
associated with increased OC discontinuation (Table 2).
Among DMPA users in bivariable analyses, no sexual partner, nausea, excessive night
sweats and loss of appetite or weight were significantly associated with an increased hazard
of discontinuation. Having a primary partner spend any nights away from home in the last
month and baseline CD4 count 201–499 cells/mm3 were protective against discontinuation.
In multivariable analyses, no sexual partner (HR 2.00; 95% CI 1.12, 3.58) and nausea (HR
1.84; 95% CI 1.02, 3.34) were significantly associated with an increased hazard of
discontinuation and excessive night sweats (HR 1.80; 95% CI 0.95, 3.40) was marginally
associated with increased DMPA discontinuation (Table 3).
Discussion
In this prospective, multi-site cohort study of hormonal contraceptive use among HIV-
infected women, overall median time to discontinuation within the eight year study period
was relatively long; over 35 months for OC users and 19 months for DMPA users. In
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sensitivity analyses, median time to discontinuation did not change dramatically when time
on HC between seroconversion and study enrollment was included or when the study
population was restricted to women on HC at study enrollment. Many women were enrolled
in the study soon after HIV seroconversion, therefore time on HC after seroconversion and
before study entry was generally short. In a similar analysis of HC discontinuation among
HIV-uninfected women, median duration of use from study entry was the same for DMPA
users (19 months) but shorter for OC users (16 months), however participants were only
followed for 15–24 months32. The median time to discontinuation of any highly effective
method was similar; nearly 36 months for OC users and 22 months for DMPA users.
Despite the extensive duration of HC use, 65% of women discontinued their original method
at some point during follow-up.
While overall OC use was nearly twice as long as DMPA use, the length of time on a
method varied by country. Living in Zimbabwe, compared to Uganda, was associated with
over a 60% reduction in the hazard of discontinuing OCs. In contrast, among DMPA users,
country was not an important factor for time to discontinuation. Historical country-specific
programming may explain these observations. In Zimbabwe, family planning programs have
traditionally emphasized OC use over DMPA and 41% of currently married Zimbabwean
women use OCs33. In Uganda women tend to prefer injectables, however fewer women
overall use modern contraception and only 14% use injectables34.
Little research on HC use by HIV-infected women has focused on contraceptive use over an
extended time period or included time-varying factors related to contraceptive use35–37. By
incorporating time-varying factors into our study, including side-effects related to HIV
infection and HC use, as well as sexual behavior characteristics, we were able to assess how
these factors influence HC discontinuation over time.
Throughout the follow-up period, few HIV-related side effects were associated with
increased HC discontinuation. Symptoms suggesting opportunistic infections have
previously been inversely associated with HC use38, however, in our study this was not the
case. Consistent with previous work, higher CD4 counts were protective against DMPA
discontinuation, although these results were not statistically significant39. The reverse was
true for OC users; however, due to sparse data the estimates for the association between
CD4 count and discontinuation among OC users are imprecise. Women in our analysis were
censored at HAART initiation (HAART was not available throughout the study); therefore
we cannot assess the impact of HAART use on HC discontinuation. However, our results
suggest that pre-HAART initiation, HIV-related symptoms do not contribute significantly to
HC discontinuation.
Few non-HIV related side-effects or health conditions were significant predictors of HC
discontinuation in our study. Previous work has shown that side effects are often a primary
reason for HC discontinuation37,40. In a similar analysis among HIV-uninfected women,
side-effects including breast tenderness, nausea and bleeding problems (DMPA users) were
significantly associated with HC discontinuation32. However, in our analysis only nausea
was associated with DMPA discontinuation. Having a cervical infection was the only other
health condition associated with OC discontinuation. The most commonly reported reason
for discontinuation of original method was ‘other non-medical reasons’ (59% among OC
users and 22% among DMPA users), suggesting that the decision to switch contraceptive
methods may have more to do with preferences unrelated to side-effects.
Consistent with previous studies, not having a partner was strongly associated with
discontinuation for both DMPA and OC users41–43. However, at the time of original method
discontinuation, 86% of OC users and 79% of DMPA users reported having a primary
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partner. Such a large proportion of HIV-infected women with sexual partners highlights the
importance of HC as an option for managing their reproductive choices.
Among HIV-uninfected women, younger age has been associated with HC
discontinuation32,44. In our study, younger age (19–24 years) at method start was associated
with discontinuation for OC users, although the results were not statistically significant. Age
was not associated with DMPA discontinuation. Upon learning they are HIV-infected, many
women choose to switch from combined oral contraceptive pills to an injectable
contraceptive8,32,45. Our results suggest that injectables may be preferable in particular for
younger HIV-infected women interested in long-term HC use46.
Discontinuation of a woman’s original method due to pregnancy, intended or unintended,
was notably low in our analysis. Other studies have reported parity as being associated with
HC use35,38. However, neither having two or more children at baseline or breastfeeding
during follow-up (for DMPA users) were associated with HC discontinuation. This is likely
explained by parity being relatively high among study participants, since most women
already had at least two children. Further, while HIV-infected women may continue to
desire children, they may choose to have fewer children overall, compared to HIV-
uninfected women10–12.
Our study has several important strengths. We were able to collect extensive information on
both clinical and behavioral factors that influence contraceptive use, and had the ability to
analyze how these factors changed over an extended period of time. In addition, we
evaluated how morbidity associated with HIV infection and disease progression influenced
contraceptive use over time. A limitation of our study was the inability to account for
multiple contraceptive method switches and only evaluate the median time to first method
switch. In addition, because HAART was not available for the entire study women were
censored at HAART initiation and therefore we could not evaluate contraceptive use after
treatment initiation. Fertility preferences were not included in the multivariable analysis,
however at the time of discontinuation only 5% of women reported discontinuing due to
intended or unintended pregnancy, suggesting that fertility intention was not a primary
reason for HC discontinuation.
Providing safe and effective contraceptive choices for HIV-infected women is critical to
prevent unintended pregnancies and reduce vertical HIV transmission. As access to HAART
expands and the risk of vertical transmission decreases, HIV-infected women will
increasingly need effective contraception to attain their reproductive goals. Our results
suggest that HC methods are acceptable and feasible for HIV-infected women to use over
longer periods of time, but that women often chose to discontinue a method for a variety of
reasons. Providing HIV-infected women with an expanded range of contraceptive choices,
including longer-acting reversible methods (e.g., IUDs, implants), is urgently needed.
Access to a range of contraceptive options and ongoing contraceptive counseling are
essential components of improving HIV-infected women’s reproductive control and
decreasing HIV transmission.
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Figure 1. Kaplan-Meier estimation of discontinuation probabilities by contraceptive groups
Log rank test for the distributions of time to discontinuation (p-value): 0.069.
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Figure 2. Kaplan-Meier estimation of discontinuation probabilities by contraceptive groups and
country
Log rank test for the distributions of time to discontinuation (p-value): 0.021.
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Table 2
Factors associated with discontinuation of OCs among HIV-infected women in Uganda
and Zimbabwe
Additional factors investigated which were not significant in bivariable models include: living with a partner,
education, parity, currently breastfeeding, primary partner’s HIV status, primary partner spent nights away,
alcohol use, severe headaches, nausea, breast tenderness, bleeding between periods, abnormal vaginal
discharge, current vaginal infection (TV, BV, Candida, unexplained fever, excessive night sweats, loss of











Zimbabwe 0.48 (0.26, 0.84) 0.01 0.39 (0.18, 0.83) 0.01
Age at method start (years)
   30+ 1.00 1.00
   25–29 0.96 (0.44, 2.10) 0.92 0.98 (0.45, 2.10) 0.95
   19–24 2.00 (0.96, 4.14) 0.06 1.72 (0.74, 4.01) 0.21
Time-varying covariates
Coital Frequency (typical month in last 3 months)
   0–14 acts 1.00 N/A
   15–29 acts 0.48 (0.20, 1.16) 0.10 N/A
   30+ acts 0.67 (0.15, 2.97) 0.60 N/A
Condom use (typical month in last 3 months)
   Always 1.00 1.00
   Sometimes 1.32 (0.36, 4.83) 0.67 1.03 (0.28, 3.79) 0.97
   Never 2.43 (1.01, 5.85) 0.05 1.26 (0.51, 3.12) 0.62
   No sexual partner 7.02 (2.94, 16.78) <0.01 7.18 (3.05, 16.88) <0.01
Participant behavioral risk in last 3 months 5.81 (1.18, 28.53) 0.03 N/A
Current cervical infection (GC or CT) 2.01 (0.87, 4.66) 0.10 1.99 (0.90, 4.41) 0.09
CD4 count
   ≤200 cells/mm3 1.00 1.00
   201–499 cells/mm3 0.68 (0.21, 2.21) 0.52 1.22 (0.30, 4.95) 0.78
   ≥500 cells/mm3 1.45 (0.49, 4.29) 0.50 1.54 (0.45, 5.33) 0.49
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Table 3
Factors associated with discontinuation of DMPA among HIV-infected women in Uganda
and Zimbabwe
Additional factors investigated which were not significant in bivariable models include: living with a partner,
education, parity, participant’s behavioral risk, primary partner’s HIV status, alcohol use, coital frequency,
severe headaches, breast tenderness, bleeding between periods, abnormal vaginal discharge, current vaginal
infection (TV, BV, Candida), current cervical infection (CT or GC), unexplained fever and fatigue that








Zimbabwe 1.10 (0.75, 1.63) 0.63 0.85 (0.54, 1.34) 0.49
Age at method start (years)
   30+ 1.00 1.00
   25–29 1.08 (0.66, 1.75) 0.77 1.17 (0.71, 1.92) 0.53
   19–24 1.05 (0.63, 1.75) 0.85 1.03 (0.60, 1.75) 0.93
Time-varying covariates
Condom use (typical month in last 3 months)
   Always 1.00 1.00
   Sometimes 0.89 (0.49, 1.63) 0.71 0.86 (0.45, 1.65) 0.65
   Never 0.76 (0.46, 1.24) 0.26 0.68 (0.38, 1.21) 0.18
   No sexual partner 2.24 (1.22, 4.11) <0.01 2.00 (1.12, 3.58) 0.02
Primary partner spend any nights away from home in the last 30 0.72 (0.48, 1.07) 0.10 N/A
Nausea 1.94 (1.05, 3.59) 0.04 1.84 (1.02, 3.34) 0.04
Excessive night sweats 2.08 (1.11, 3.90) 0.02 1.80 (0.95, 3.40) 0.07
Loss of appetite or weight 1.89 (0.96, 3.71) 0.06 N/A
CD4 count
   ≤200 cells/mm3 1.00 1.00
   201–499 cells/mm3 0.52 (0.24, 1.11) 0.09 0.58 (0.27, 1.24) 0.16
   ≥500 cells/mm3 0.57 (0.26, 1.21) 0.14 0.72 (0.33, 1.54) 0.39
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